FDA approves return of popular Primatene Mist asthma inhaler

Associated Press |

TRENTON, N.J. (AP) — A new version of the once-popular asthma inhaler Primatene Mist will soon return to U.S. stores.

The Food and Drug Administration approved the over-the-counter aerosol inhaler late Wednesday. It's for temporary relief of mild, intermittent asthma symptoms in people ages 12 and up.

The original Primatene Mist was pulled from store shelves seven years ago because the inhaler's ozone-depleting propellant had been banned. That version had been marketed for half a century, including in memorable TV ads .

The new product from Amphastar Pharmaceuticals uses a safer propellant. The inhaler will cost about $25 and should be available by the end of the year.

The FDA said in a statement that the inhaler should not be substituted for prescription treatments or used by people with severe asthma.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Goldrea Resources Corp.

Goldrea Resources Corp is engaged in the acquisition, exploration and development of mineral properties located in North America.